Titel:
An International, Phase 3, Randomized, Multicenter, Open-label Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With KIT Exon 11 and Co-occurring KIT Exons 17 and/or 18 Mutations Who Were Previously Treated With Imatinib
Phase:
III
Kontakt:
Sabine Wieder / Study Nurse
Prüfer:
Prof. Dr. Georg Martin Haag
Registrierung:
Die Studie ist bei den U.S. National Institutes of Health(ClinicalTrials.gov) registriert. Siehe
NCT05734105
